Eli Lilly and Company (NYSE:LLY) is Jennison Associates LLC’s 5th Largest Position

Jennison Associates LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 9.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,597,612 shares of the company’s stock after selling 810,001 shares during the quarter. Eli Lilly and Company accounts for 3.3% of Jennison Associates LLC’s investment portfolio, making the stock its 5th largest holding. Jennison Associates LLC owned 0.80% of Eli Lilly and Company worth $4,428,800,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after purchasing an additional 659,838 shares during the period. Morgan Stanley lifted its stake in shares of Eli Lilly and Company by 0.7% in the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock valued at $6,738,605,000 after purchasing an additional 83,915 shares during the period. Northern Trust Corp lifted its stake in shares of Eli Lilly and Company by 3.6% in the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock valued at $5,456,314,000 after purchasing an additional 355,317 shares during the period. International Assets Investment Management LLC lifted its stake in shares of Eli Lilly and Company by 61,268.8% in the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in shares of Eli Lilly and Company by 2.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 4,435,311 shares of the company’s stock valued at $2,382,339,000 after purchasing an additional 88,016 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $731.32 on Tuesday. Eli Lilly and Company has a 1 year low of $370.68 and a 1 year high of $800.78. The firm has a 50 day moving average price of $763.83 and a 200 day moving average price of $662.78. The company has a market cap of $694.87 billion, a price-to-earnings ratio of 126.09, a PEG ratio of 1.58 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same period in the previous year, the firm earned $2.09 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 28.1% on a year-over-year basis. Sell-side analysts predict that Eli Lilly and Company will post 12.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of research reports. Citigroup lifted their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Truist Financial restated a “buy” rating and set a $850.00 target price on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Wells Fargo & Company lifted their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. Morgan Stanley lifted their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research report on Friday, February 16th. Finally, Barclays lifted their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 7th. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.